IP Library › Granted Patent US 40,418
Granted Patent E1
US 40,418 · App. 11/222,485 · Granted Jul 1, 2008

Treatment of neoplasms with CCI-779/EKB-569 combination

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 40,418
App. No.
11/222,485
Granted
Jul 1, 2008
Kind
E1
Abstract

This invention provides the use of a combination of CCI-779 and EKB-569 in the treatment of neoplasms.

Claims (27)

1. A method of treating a neoplasm in which uncontrolled cell proliferation results from deregulation of epidermal growth factor receptor ( EGFR ) kinase in a mammal in need thereof, which comprises providing to said mammal a synergistically effective amount of a combination comprising rapamycin 42 - ester with 3 - hydroxy - 2 -( hydroxymethyl )- 2 - methylpropionic acid (CCI-779) and 4 - dimethylamino - but - 2 - enoic acid [ 4 -( 3 - chloro - 4 - fluoro - phenylamino )- 3 - cyano - 7 - ethoxy - quinolin - 6 - yl] - amide (EKB-569).

2. The method according to claim 1 , wherein the neoplasm is renal cancer.

3. The method according to claim 1 , wherein the neoplasm is soft tissue sarcoma.

4. The method according to claim 1 , wherein the neoplasm is breast cancer.

5. The method according to claim 1 , wherein the neoplasm is a neuroendocrine tumor of the lung.

6. The method according to claim 1 , wherein the neoplasm is cervical cancer.

7. The method according to claim 1 , wherein the neoplasm is uterine cancer.

8. The method according to claim 1 , wherein the neoplasm is a head and neck cancer.

9. The method according to claim 1 , wherein the neoplasm is glioma.

10. The method according to claim 1 , wherein the neoplasm is non-small cell lung cancer.

11. The method according to claim 1 , wherein the neoplasm is prostate cancer.

12. The method according to claim 1 , wherein the neoplasm is pancreatic cancer.

13. The method according to claim 1 , wherein the neoplasm is lymphoma.

14. The method according to claim 1 , wherein the neoplasm is melanoma.

15. The method according to claim 1 , wherein the neoplasm is small cell lung cancer.

16. The method according to claim 1 , wherein the neoplasm is ovarian cancer.

17. The A method according to claim 1 , wherein the neoplasm is of treating colon cancer in a mammal in need thereof, which comprises providing to said mammal a synergistically effective amount of a combination comprising rapamycin 42 - ester with 3 - hydroxy - 2 ( hydroxymethyl )- 2 - methylpropionic acid ( CCI - 779 ) and 4 - dimethylamino - but - 2 - enoic acid [ 4 -( 3 - chloro - 4 - fluoro - phenylamino )- 3 - cyano - 7 - ethoxy - quinolin - 6 - yl] - amide ( EKB - 569 ).

18. The method according to claim 1 , wherein the neoplasm is esophageal cancer.

19. The method according to claim 1 , wherein the neoplasm is gastric cancer.

20. The method according to claim 1 , wherein the neoplasm is leukemia.

21. The A method according to claim 1 , wherein the neoplasm is of treating colorectal cancer in a mammal in need thereof, which comprises providing to said mammal a synergistically effective amount of a combination comprising rapamycin 42 - ester with 3 - hydroxy - 2 ( hydroxymethyl )- 2 - methylpropionic acid ( CCI - 779 ) and 4 - dimethylamino - but - 2 - enoic acid [ 4 -( 3 - chloro - 4 - fluoro - phenylamino )- 3 - cyano - 7 - ethoxy - quinolin - 6 - yl] - amide ( EKB - 569 ).

22. The method according to claim 1 , wherein the neoplasm is unknown primary cancer.

23. A method of treating a neoplasm in which uncontrolled cell proliferation results from deregulation of epidermal growth factor receptor ( EGFR ) kinase in a mammal in need thereof, which comprises providing to said mammal an effective amount of a synergistic combination comprising rapamycin 42 - ester with 3 - hydroxy - 2 -( hydroxymethyl )- 2 - methylpropionic acid (CCI-779) and 4 - dimethylamino - but - 2 - enoic acid [ 4 -( 3 - chloro - 4 - fluoro - phenylamino )- 3 - cyano - 7 - ethoxy - quinolin - 6 - yl] - amide (EKB-569), wherein either CCI-779, EKB-569, or both are provided in subtherapeutically effective amounts.

24. The method according to claim 23 in which CCI-779 is provided in a subtherapeutically effective amount.

25. The method according to claim 23 in which EKB-569 is provided in a subtherapeutically effective amount.

26. The method according to claim 23 in which both CCI-779 and EKB-569 are provided in subtherapeutically effective amounts.

27. An antineoplastic combination useful in treatment of neoplasms in which uncontrolled cell proliferation results from by deregulation of epidermal growth factor receptor kinase which comprises an antineoplastic effective amount of a synergistic combination of rapamycin 42 - ester with 3 - hydroxy - 2 -( hydroxymethyl )- 2 - methylpropionic acid (CCI-779) and 4 - dimethylamino - but - 2 - enoic acid [ 4 -( 3 - chloro - 4 - fluoro - phenylamino )- 3 - cyano - 7 - ethoxy - quinolin - 6 - yl] - amide (EKB-569).